In our study, we found that targeting CDK7 increased the toxic effect of tamoxifen in sensitive and resistant breast cancer cells as well as in vivo models by targeting important proteins, such as ER and MYC, and essential pathways in breast cancer progression (STAT3 and β-catenin). Here, ESR1 is linked to breast cancer.